Persuasive evidence has accumulated demonstrating a strong negative association between rheumatoid arthritis and schizophrenia at the population level. Explanations for this phenomenon have taken into consideration immunological, biochemical, and genetic factors. In this article, we examine these and other factors in closer detail. We then propose hypotheses at the molecular level that might account for the negative association between the two diseases. These hypotheses may provide clues for our colleagues in molecular biology as they search for candidate genes, "anti-genes," and molecular mechanisms relevant to schizophrenia. . This negative association appears specific to schizophrenia; Baldwin (1979, 1980), using a recordlinkage approach, found only one case of schizophrenia among 2,122 patients with rheumatoid arthritis (relative risk of 0.15%), whereas nonpsychotic depression and affective psychosis carried relative risks of 0.94 percent and 1.38 percent, respectively, among these patients with rheumatoid arthritis. Allebeck and colleagues, in an attempt to reproduce these findings, found no substantial difference between observed and expected numbers of rheumatoid arthritis in 3,978 cases of "neurosis," whereas they found that the incidence of rheumatoid arthritis was half the expected value in 1,190 cases of schizophrenia. The incidence of rheumatoid arthritis was also surprise ingly low in 621 patients with affective psychosis; this sample was relatively small, not well defined, and results were not statistically significant (Allebeck et al. 1985) . It is important to note that these population studies have not, as a rule, been well controlled, nor have they been based on carefully gathered, operationalized diagnostic criteria such as
. This negative association appears specific to schizophrenia; Baldwin (1979, 1980) , using a recordlinkage approach, found only one case of schizophrenia among 2,122 patients with rheumatoid arthritis (relative risk of 0.15%), whereas nonpsychotic depression and affective psychosis carried relative risks of 0.94 percent and 1.38 percent, respectively, among these patients with rheumatoid arthritis. Allebeck and colleagues, in an attempt to reproduce these findings, found no substantial difference between observed and expected numbers of rheumatoid arthritis in 3,978 cases of "neurosis," whereas they found that the incidence of rheumatoid arthritis was half the expected value in 1,190 cases of schizophrenia. The incidence of rheumatoid arthritis was also surprise ingly low in 621 patients with affective psychosis; this sample was relatively small, not well defined, and results were not statistically significant (Allebeck et al. 1985 Spitzer et al. 1978) . It is well established that medical problems are underdiagnosed in the chronically mentally ill population (Koran et al. 1989) , and therefore the most credible of all these studies are those in which schizophrenic patients were directly examined by the investigators (e.g., Gattaz et al. 1980; Mellsop et al. 1974 ).
In 1984, Bates and Van Damm performed an epidemiologic study of 1,400 British Columbia coastal Indians, an ethnic group whose arthritis disease rate is 14 times higher than that of Caucasian populations. They found an extremely low incidence of schizophrenia in this group (approximately 0.01%). They pointed out that coastal Indians were believed to possess an enzyme mutation that severely lowers production of arachidonic acid, perhaps also lowering levels of one of its metabolites, prostaglandin E2. In 1974, Mellsop and coworkers examined 301 randomly selected middle-aged women with schizophrenia and were unable to find any clinical or radiologic evidence of rheumatoid arthritis. They then concluded that rheumatoid arthritis and schizophrenia must "occur in genetically different subjects" (p. 251).
Schizophrenia and Rheumatoid Arthritis: Anything in Common?
How might one explain such hypothetical "genetic differences" between subjects with schizophrenia and those with rheumatoid arthritis? Is there any possible overlap in etiology or pathophysiology between the two diseases that could account for their negative association at a population Ievel7 And if so, does this provide some useful directions for future research in schizophrenia? (Of course, we well recognize that schizophrenia is probably not a single disease entity, but that instead it most likely represents a syndrome or final common pathway caused by several different etiopathogenetic processes. In the following discussion, we will consider only the "form" of schizophrenia that shares some processes with rheumatoid arthritis.)
Rheumatoid arthritis is considered, first and foremost, to be an autoimmune illness that is prostaglandindependent. There are various wellestablished human leukocyte antigen (HLA) associations in rheumatoid arthritis and related diseases, including a strongly positive association between rheumatoid arthritis and HLA-DRw4, and a negative association with HLA-A1 and HLA-A1/B8 (Gilliland and Mannik 1983; McDermott et al. 1986; Oilier et al. 1986; Spector and SUman 1987) .
Based on research evidence from various sources, several investigators have suggested that a primary or secondary immune-related process may be taking place in some schizophrenic patients as well (e.g., Goldstein et al. 1980; Mendlewicz et al. 1981; Delisi 1984; Pert et al. 1988; Stevens 1988; Henneberg et al. 1990) . McAllister et al. (1989) recently demonstrated increased numbers of CD5 + B-lymphocytes in schizophrenic patients, while Henneberg and coworkers (1990) found significant increases in the numbers of Pan T and T-helper cells in schizophrenic patients compared with numbers of these cells in control subjects. Spivak et al. (1991) have reported a high frequency of cold agglutinin titers in schizophrenic patients, compared with titers found in patients with bipolar or unipolar affective disorder or in normal controls.
A small group of studies also has shown that schizophrenic patients may have abnormal arachidonic acid or prostaglandin metabolism (Horrobin et al. 1978 (Horrobin et al. , 1989 Mathe et al. 1980; Horrobin and Huang 1983; Demisch et al. 1987) . See figure 1 for a schematic outline of those aspects of lipid metabolism that might be pertinent to this discussion. In addition, there are many reports of associations between certain HLA haplotypes and certain subtypes of schizophrenia, and genetic linkage studies between the HLA locus and schizophrenia have been carried out in several pedigrees (Eberhard et al. 1975; Smeraldi et al. 1976; Julien et al. 1977; Ivanyi et al. 1978; McGuffin et al. 1978 McGuffin et al. , 1981 McGuffin et al. , 1983 Asaka et al. 1981; Gattaz et al. 1981; Mendlewicz et al. 1981; Sturt and McGuffin 1985; McGuffin and Sturt 1986) . Unlike the case for rheumatoid arthritis, however, the association between schizophrenia and HLA haplotypes is controversial and far from clear-cut; major linkage studies have shown no linkage between the HLA locus and schizophrenia (e.g., Goldin et al. 1987) .
In addition to the immune system findings, rheumatoid arthritis shows a strong genetic component inferable from twin and family studies just as schizophrenia does. Severe rheumatoid arthritis is found at four times the expected rate in first-degree relatives of probands with the illness, and twin studies demonstrate a monozygotic concordance rate of 25 to 40 percent (Lawrence 1970) . Rheumatoid arthritis also shows a variable age of onset and a widely varying clinical presentation. This, in combination with a number of genetic and family studies, has led researchers to conclude that rheuma- 
Explanations for the Negative Association
A number of suggestions at the metabolic and biochemical level have been proposed to explain the negative association between rheumatoid arthritis and some possible forms of schizophrenia (Malek-Ahmadi 1985; Spector and Silman 1987) . Fields of inquiry have included the following:
1. The role of prostaglandins and related precursors (arachidonic acid and essential fatty acids; see figure  1 ). Increased prostaglandins have been found in the synovial fluid of patients with rheumatoid arthritis, and anti-inflammatory agents with prostaglandin-synthetase-inhibiting activity are an effective form of treatment for this illness (Gilliland and Mannik 1983) . Both increased prostaglandins (Horrobin et al. 1978; Horrobin and Huang 1983) and decreased prostaglandins (Feldberg 1976) have been proposed to play a role in schizophrenia, although cerebrospinal fluid findings have been inconsistent (Mathe et al. 1980; Mathe and Sedvall 1986) . More recently, Horrobin et al. (1989) found a significant reduction in n-3 essential fatty acids (those derived from linoleic acid) and a significant elevation in n-6 essential fatty acids (derived from alpha-linolenic acid) in the plasma of three different groups of schizophrenic patients when compared with plasma levels in controls.
2. Histocompatibility factors and other immune system-related factors. Gattaz and coworkers (1980, 1981) have hypothesized that the presence of HLA-B27 antigen serves as a protective factor in both schizophrenia and arthropathy; they found no cases of arthropathy in a sample of schizophrenic subjects with HLA-B27, and likewise found no schizophrenia in a sample of arthritic patients with HLA-B27. Mellsop and co-workers (1973) specifically searched for but were unable to demonstrate the presence of significant autoimmune serological reactions in schizophrenic subjects. It also has been suggested that other HLA factors and other immune system modulators may play a role in the negative association between the two diseases (Spector and Silman 1987; McAllister et al. 1989) .
3. The role of serum beta-endorphin. Decreased levels of serum betaendorphin have been reported in rheumatoid arthritis (Denko et al. 1982) , whereas both increased and normal levels have been found in some schizophrenic patients (Ross et al. 1979; Brambilla et al. 1984) .
4. The metabolism of tryptophan and serotonin. Taylor (1978) has concluded that there is an increased binding of tryptophan to serum proteins-and thus a decreased bioavailability-in rheumatoid arthritis, while there may be an excessive intracellular uptake in some forms of schizophrenia. He has suggested that this inverse metabolic relationship may explain the negative association between the two illnesses. Serotonin is increasingly being recognized as a neurotransmitter that may play an important role in some forms of schizophrenia (Csemansky et al. 1990) .
In addition to these fields of inquiry, we suggest a fifth possible area: the role of prolactin-and hence dopamine-in immunomodulation. Prolactin has important immunoregulatory properties. Human lymphocytes have prolactin receptors, and prolactin appears to play a role in the development and maintenance of normal lymphocyte function (Russell et al. 1988) . Prolactin restores immunocompetence in immunecompromised mice (Russell 1989) , while hypoprolactinemia impairs lymphocyte responses to antigenic stimuli in experimental animals (Bemton et al. 1988 ). The dopamine agonist bromocriptine, through inhibition of prolactin, suppresses various immune reactions, including adjuvant arthritis and experimental allergic encephalitis (Nagy et al. 1983; Bemton et al. 1988 ); administration of prolactin reverses some of these effects.
One could thus hypothesize that the state of dopaminergic hyperactivity, which has been proposed to occur in some forms of schizophrenia, could result in a state of relative hypoprolactinemia. This state would result in a suppression of various lymphocyte-modulated immune reactions, including the autoimmune reactions that give rise to rheumatoid arthritis. A model for this hypothetical mechanism was recently suggested by a report in which several patients with a longstanding autoimmune iridocyclitis underwent complete remission after incidental treatment with bromocriptine for unrelated conditions (Hedner and Bynke 1985) . 
Recommendations for Future Research
Whatever the exact model for the etiologic and pathophysiologic relationship between some forms of schizophrenia and some forms of rheumatoid arthritis, the negative association between the two diseases appears robust. In fact, "some of the strongest and most consistent evidence of a relationship between a form of mental illness and physical disease exists for schizophrenia and rheumatoid arthritis" (Harris 1988, p. 90). Given this negative assodation, there are several fruitful areas for future research in the molecular biology of schizophrenia. These indude consideration of gene products and regions in the genome that could be "protective" in either schizophrenia or rheumatoid arthritis and might best be conceptualized as candidate "anti-genes" (Gurling 1986).
One such area is the fatty-add desaturase systems (enzymes involved in essential fatty add interconversion and metabolism). Both the n-3 and the n-6 series of essential fatty adds are basic precursors for the prostaglandins via phospholipid and arachidonic add metabolism (see figure 1) and both serve a structural role in all cell membranes. The n-6 essential fatty adds have been shown to influence the amount of dopamine released from the caudate nucleus in response to electrical stimulation. It also has been suggested that both series influence normal presynaptic control of dopamine release (Davidson et al. 1988) . Horrobin and Huang (1983) have proposed that a defective desaturase enzyme could lower levels of n-6 fatty-add metabolites; this scenario could predispose an individual to schizophrenia and also lead to an underproduction of prostaglandins. It is this same underproduction of prostaglandins that protects the individual from the myriad environmental and multifactorial insults that otherwise would lead to rheumatoid arthritis (Horrobin and Huang 1983) .
The phospholipase systems, induding phospholipase-A2 inhibiting proteins, represent another area of potentially fruitful research. These metabolic systems are involved in the synthetic pathway from phospholipids to arachidonic add, as well as in the metabolism of aradiidonic add into prostanoids and eicosanoids (see Rotrosen and Wolkin 1987) .
Horrobin and coworkers (1989) have recently suggested that "The basic physiology and biochemistry of . . . eicosanoids, and their effects on neural function, mean that they are just as likely as neurotransmitters to contribute to abnormal psychiatric states" (p. 567). Associations among membrane phospholipids, neurotransmitters, and schizophrenia have been reported by various investigators over the years (Stevens 1972; Feldberg 1976; Hirata and Axelrod 1980; Rotrosen et al. 1980; Henn and Henn 1982; Hitzemann and Gaver 1982) . Membrane fluidity, which is in turn influenced by phospholipid composition and methylation, affects binding affinities for dopamine, norepinephrine, serotonin, and endogenous opiates (Heron et al. 1980; Hirata and Axelrod 1980; Cimino et al. 1984) .
In two separate studies, Gattaz et al. (1987 Gattaz et al. ( , 1990 ) demonstrated increased serum phospholipase-A2 activity in schizophrenia and discussed the metabolic implications. They also noted that some of the phospholipase-A2-inhibiting proteins may be under the influence of the HLA locus. Hibbeln and coworkers (1989) proposed that disturbances in lipid-protein interactions by phospholipase-A2 may be a predisposing factor to serious affective illness; they described in detail the many known influences of phospholipase-A2 on systems important in neuronal function. Human phospholipase-A2 has been mapped to chromosome 12 and shares a marked homology with snake-venom phospholipase (McKusick 1988) .
Alternatively, a more parsimonious research strategy might first consist of definitive identification of pathophysiologic similarities or interactions between the two diseases, which could then be followed by more targeted genetics studies. For example, the phenomenon of chronic psychosis itself may somehow secondarily produce a protective effect against developing rheumatoid arthritis in at-risk individuals, perhaps through an increase in drculating corticosteroids.
The Lewis rat model suggests a mechanism by which a defective hypothalamic-pituitary-adrenal axis response to inflammatory and immune mediators (related to a specific genetic defect at the level of gene expression for cortisol-releasing factor in the hypothalamus) results in an increased liability to environmentally induced arthritis (Sternberg et al. 1990 ). This theory raises at least two provocative questions: Do other inflammatory and autoimmune disorders also show a negative correlation with schizophrenia? And are there familial or population differences in these associations?
Increasing knowledge of the effects of dopamine and prolactin on immunomodulation suggests yet another avenue of exploration. Since pharmacologic agents with dopaminergic properties (amphetamines, bromocriptine, cocaine) alter plasma prolactin levels, it would be important to determine the incidence of rheumatoid arthritis in populations chronically exposed to these agents. In a subgroup of chronic cocaine abusers, hyperprolactinemia has been found, a condition possibly related to dopamine receptor down-regulation (Mendelson et al. 1989) ; this finding underscores the complexity of the relationship between dopaminereceptor activity and prolactin release.
Chronic exposure to dopamineblocking agents, such as neuroleptics, may result in dopamine receptor upregulation and a relative hypoprolactinemia that blunts lymphocyte responses to antigenic stimuli. Thus, we would hypothesize that individuals treated with neuroleptics will be "protected" from autoimmune inflammatory responses, such as those which occur in rheumatoid arthritis. Chronic cocaine users, on the other hand, may be prone to such reactions. Further population studies are clearly warranted.
Conclusions
In sum, we suggest that the negative association between rheumatoid arthritis and schizophrenia represents a tantalizing clue for future research in the molecular biology of these diseases and deserves further study. The factors we have proposed as possibly playing a role in both schizophrenia and rheumatoid arthritis will most likely represent genes or gene products that contribute to a liability to schizophrenia, as opposed to factors that are actually causative. Such 'liability genes" could determine an idiosyncratic immune response to a viral infection (see Pert et al. 1988) , leaving an individual prone to interference with normal brain functioning in some cases (schizophrenia) or to an autoimmune arthropathic condition in others (rheumatoid arthritis). The implications of a possible etiologic relationship between the two diseases must be carefully distinguished from those of a possible pathophysiologic relationship.
Future researchers will find it useful to seek out pedigrees containing both schizophrenia and rheumatoid arthritis in order to examine genotypic and environmental differences within families. "Further use of family studies should also be made to determine whether unaffected relatives are also 'protected' from either schizophrenia or rheumatoid arthritis" (Spector and Silman 1987, p. 309) . We have already observed a monozygotic adult twin pair discordant for schizophrenia in which only the nonschizophrenic twin has rheumatoid arthritis. We also have begun studying a large multiplex schizophrenia pedigree, which includes an "obligate female carrier" of the hypothetical schizophrenia gene(s) who is the sister of a schizophrenic patient and the mother of four schizophrenic adults. The "obligate carrier" herself has no major psychiatric illness but suffers from severe rheumatoid arthritis. McAllister et al. (1989) , who demonstrated an increase in CD5 + B cells in schizophrenic patients similar to that reported for patients with rheumatoid arthritis, have suggested that "genetic and/or environmental factors may cause the selection of a putative idiotype that contributes to the development of either disorder in certain patients" (p. 894).
Although the negative association between the two diseases offers fascinating avenues for further probes into the molecular biology of some forms of schizophrenia, we do not mean to suggest that any easy breakthroughs lie just around the bend. The real nature of the relationship between rheumatoid arthritis and schizophrenia will undoubtedly turn out to be subtle and complex, and probably multifactorial. We must be prepared, in the words of Alfred North Whitehead (1971) , to "seek simplicity and distrust it" (p. 49). Psychiatry, 141:1183 Psychiatry, 141: -1188 Psychiatry, 141: , 1984 Cimino, M.; Vantini, G.; Algeri, S.; Curatola, G.; Fezzoli, C; and Stramentinoli, G. Age-related modification of a dopaminergic and betaadrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with 5-adenosylmethionine. Life Sciences, 34:2029 Sciences, 34: -2039 Sciences, 34: , 1984 Csemansky, J.G.; King, R.J.; Faustman, W.O.; Moses, J., Jr.; Poscher, M.D.; and Faull, K.F. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. British journal of Psychiatry, 156:501-507, 1990 . Davidson, B.; Kurstjens, N.P.; Patton, J.; and Cantrill, R.C. Essential fatty acids modulate apomorphine activity at dopamine receptors in cat caudate slices. European Journal of Pharmacology, 149:317-322, 1988 . Delisi, L.E. Is immune dysfunction associated with schizophrenia7 A review of the data. Psychopharmacology Bulletin, 20:509-513, 1984 . Demisch, L.; Gerbaldo, H.; Gebhart, P.; Georgi, K. ; and Bochnik, H.J. Incorporation of 14C-arachidonic acid into platelet phospholipids of untreated patients with schizophrenia or schizophrenic disorders. Psychiatry Research, 22:275-282, 1987. Gurling, H. Candidate genes and favoured loci: Strategies for molecular genetics research into schizophrenia, manic depression, autism, alcoholism and Alzheimer's disease. Psychiatric Development, 4:289-309, 1986. Harris, A.E. Physical disease and schizophrenia. Schizophrenia Bulletin, 14:85-96, 1988 . Hedner, L.P., and Bynke, G. Endogenous iridocyclitis relieved during treatment with bromocriptine. American Journal of Ophthalmology, 100:618, 1985 . Henn, F., and Henn, S. Phospholipids as markers for schizophrenia. In: Usdin, E., and Hanin, I., eds.
References

Biological Markers in Psychiatry and
